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Background. Malaria prophylaxis is recommended for persons with sickle cell disease (SCD), but the value of
this has been questioned. The aim of this study was to ﬁnd out whether intermittent preventive treatment (IPT) with
a ﬁxed-dose combination of meﬂoquine-artesunate (MQAS) or sulfadoxine-pyrimethamine plus amodiaquine
(SPAQ) was more effective than daily proguanil for malaria prevention in subjects with SCD.
Methods. Patients with SCD were randomized to receive daily treatment with proguanil or IPT with either
MQAS or SPAQ once every 2 months at routine clinic visits. Patients were followed up for 14 months.
Findings. A total of 270 patients with SCD were studied, with 90 in each group. Adherence to the IPT regimens
was excellent, but 57% of patients took <75% of their daily doses of proguanil. IPT was well tolerated; the most com-
mon side effects were vomiting and abdominal pain. Protective efﬁcacy against malaria, compared with daily
proguanil, was 61% (95% conﬁdence interval, 3%–84%) for MQAS and 36% (40%–70%) for SPAQ. There were
fewer outpatient illness episodes in children who received IPT than those who received proguanil.
Conclusions. IPT with MQAS administered to patients with SCD during routine clinic visits was well tolerated
and more effective in preventing malaria than daily prophylaxis with proguanil.
Clinical Trials Registration. NCT01319448 and ISRCTN46158146.
Keywords. sickle cell disease; malaria; chemoprevention; intermittent preventive treatment; prophylaxis;
meﬂoquine-artesunate; proguanil.
Although the incidence of Plasmodium falciparum in-
fection is thought to be lower in children with sickle
cell disease (SCD) than in normal children [1], the con-
sequence of malaria in SCD can be serious. Findings of
studies in Kenya [2] and Tanzania [3] in which the con-
founding effects of prophylaxis for patients with SCD
could be excluded were consistent with a reduced prev-
alence of P. falciparum parasitemia and incidence of P.
falciparum infection in patients with HbSS, compared
with children with HbAA. However, in the Kenyan
study, mortality in children with SCD hospitalized
with malaria was substantially higher than that among
children without SCD [3]. Malaria can aggravate severe
anemia and like, other infections, can lead to crises in
children with SCD, and the complications of a crisis
precipitated by P. falciparum infection can be fatal [4,
5].Malaria prevention in SCD has, therefore, been con-
sidered to be essential in regions where malaria is en-
demic, but the evidence base for current drug policies,
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which rely mainly on daily proguanil therapy or weekly pyri-
methamine or chloroquine therapy, is extremely weak. A Co-
chrane review of malaria prophylaxis for patients with SCD
concluded that prophylaxis is beneﬁcial, with fewer episodes
of malaria, higher mean hemoglobin concentrations, fewer
transfusions, fewer hospital admissions, and fewer sickle cell
crises in patients receiving prophylaxis [6], but the review in-
cluded only 2 small studies, one from Kampala in 1965,
which involved administration of chloroquine plus benzathine
penicillin for 12 months [7], and one from Nigeria in 2003, in
which 97 patients were randomized to receive daily proguanil
therapy, weekly pyrimethamine therapy, or placebo for 9
months [8]. Studies not in the review included a placebo-
controlled trial of 60 patients in Senegal that showed that month-
ly sulfadoxine-pyrimethamine (SP) treatment during the trans-
mission season was well tolerated and reduced morbidity [9]; a
study in Uganda, with just 1 month of follow-up, that suggested
that weekly chloroquine therapy was less effective than monthly
SP therapy [10]; and a study in Nigeria that indicated that weekly
meﬂoquine (MQ) was well tolerated and more effective than
daily proguanil [11]. Several small surveys of patients with SCD
in Nigeria who received daily proguanil or weekly pyrimeth-
amine prophylaxis have found that malaria parasitemia is com-
mon and attributed this ﬁnding to poor compliance and
resistance [12–14]. The prevalence of mutations in the genes en-
coding dihydrofolate reductase (dhfr) and dihydropteroate syn-
thase (dhps) has been little studied but appears to be high [15].
Adherence to a daily or weekly prophylactic regimen is likely
to be poor and difﬁcult to sustain over long periods. The nation-
al antimalarial policy in Nigeria for protection of patients with
SCD against malaria at the time that this trial was conducted
was daily proguanil, and proguanil prophylaxis continues to
be used widely in Nigeria, although more-recent guidelines
(from 2011) state that, because proguanil may not be effective,
patients with SCD should rely on long-lasting insecticide-
treated bed nets and, if they have malaria, prompt treatment.
Chemoprevention with drugs being given under supervision
by health workers is increasingly being used to prevent malaria
in countries of endemicity. The World Health Organization
now recommends intermittent preventive treatment (IPT) with
SP for prevention of malaria in pregnant women, administered
during antenatal clinic visits; IPT with SP in infants (IPTi),
given when children come for routine vaccinations; and, in
areas of seasonal transmission, seasonal malaria chemopreven-
tion with SP plus amodiaquine (SPAQ) for children <5 years of
age, delivered monthly at home by a community health worker.
Patients with SCD who are stable are recommended to visit the
clinic regularly, providing an opportunity to administer chemo-
prevention under supervision, but for this approach to be effec-
tive, a long-acting antimalarial drug combination is needed.
SPAQ is effective when administered monthly, but protec-
tion wanes rapidly after about 4 weeks [16]. MQ-artesunate
(MQAS), given over 3 days, is highly effective in treating un-
complicated malaria. A ﬁxed dose of MQAS developed by the
Drugs for Neglected Diseases Initiative is better tolerated, with a
lower incidence of vomiting, than the separate-tablet regimen
[17]. When the duration of protection provided by different
IPTi drug regimens given at 2, 3, and 9 months of age was es-
timated, MQ gave the longest period of protection, with an es-
timated efﬁcacy of 73% in the ﬁrst month and 73% in the
second month after treatment [18].
In Nigeria, patients with SCD who are stable are recommend-
ed to attend the clinic once every 2 months. The aim of this trial
was, therefore, to compare the efﬁcacy, safety, and tolerability of
either IPT with MQAS given over 3 days or SPAQ (a single dose
of SP plus AQ over 3 days) administered under supervision at
routine bimonthly (once every 2 months) clinic visits to the ef-
ﬁcacy, safety, and tolerability of the standard regimen of daily
proguanil in patients with SCD.
METHODS
Study Design
Study Population
This study was undertaken at the SCD clinic of the Outpatient
Unit of the University of Ilorin Teaching Hospital, Kwara state,
Nigeria. Patients aged ≥6 months and weighing ≥5 kg with a doc-
umented genotype of SS or SC were invited to participate. Those
who had an acute illness or any additional chronic disease, had a
known allergy to any of the study drugs, or had been treated during
the 2 weeks prior to recruitment with SP, AQ, or MQ were exclud-
ed. Signed consent was sought from the participants or their par-
ents after the aims and procedures of the study had been explained.
Randomization
A list of randomly permuted blocks of 9, generated using Stata,
version 11.1, was used to randomly assign eligible patients to re-
ceive bimonthly IPT with MQAS or SPAQ or standard daily
treatment with proguanil. Participants were asked to return to
the clinic once every 2 months for the next year to receive
their treatment and, in the case of the proguanil group, to be
given the next supply of proguanil tablets. Treatment allocations
were kept inside opaque sealed envelopes. When a participant
was enrolled, they were assigned the next envelope in numerical
sequence. Their name and the date were written on the enve-
lope, which was then opened to determine treatment allocation.
Participants were issued identiﬁcation cards bearing the partic-
ipant’s name, study number, and phone numbers of the inves-
tigators and were contacted by phone the day before each clinic
visit to remind them to attend.
Procedures at Each Scheduled Clinic Visit
Participants were asked to record any illness in a diary, and
at each clinic visit patients were asked about symptoms
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experienced since their last visit. They were then given a clinical
examination, a venous blood sample was collected for hematolog-
ical and biochemical measurements, a ﬁnger-prick blood sample
was obtained for making thick and thin blood smears for micros-
copy, and a blood spot was collected onto ﬁlter paper for poly-
merase chain reaction (PCR) detection of P. falciparum and
analysis of molecular markers of drug resistance. Nested PCR
was used to amplify fragments at loci of 3 genes in which muta-
tions are associated with pyrimethamine resistance (codons 51,
59, 108, and 164 of dhfr), sulfadoxine resistance (codons 436,
437, 540, and 581 of dhps), and chloroquine resistance (codon
81 of mdr1, which encodes multidrug resistance gene 1) [19, 20].
Drug Administration
For patients assigned to receive bimonthly IPT, the ﬁrst dose of
the 3-day regimen was administered by study staff, and the re-
maining doses were given to the participant or their caregiver to
administer at home on each of the next 2 days. For those in the
proguanil group, a dose of proguanil was administered, unused
tablets were counted, and a supply of tablets for the next 2
months was given to the participant or their caregiver. All pa-
tients were given folic acid tablets and vitamin C tablets, to be
taken daily, the standard of care for SCD in Nigeria. Study par-
ticipants were asked to return 3 days after the clinic visit to be
interviewed about adverse events over the previous 3 days and,
for those in the IPT groups, to check adherence to the home
doses by tablet counts. Those who were not able to be present
for interview were contacted by phone, and details were cross-
checked at their next visit. Participants were asked to come to
the hospital if they were unwell at any time, where they were
managed as outpatients or admitted to the pediatric ward. If a
patient had suspected malaria, a rapid diagnostic test was per-
formed to determine treatment.
The study was open label; although participants and study
physicians unblinded to treatment, laboratory staff were un-
aware of treatment allocations. Laboratory methods are de-
scribed in the Supplementary Materials. The primary end
point, for which the trial was powered, was the occurrence of
any adverse event. Secondary end points included the occur-
rence of vomiting, adherence to the regimen, the incidence of
malaria, the incidence of illnesses treated in outpatient settings,
and the incidence of illnesses treated in inpatient settings.
Statistical analysis was based on intention to treat and included
all patients who were randomized. Statistical methods are de-
scribed in the Supplementary Materials.
Malaria Case Management
Any study subject who had malaria (deﬁned on the basis of an
axillary temperature of ≥37.5°C or a history of fever or vomiting
within the last 24 hours, together with a positive results of a
malaria rapid diagnostic test) was treated with artemether/lu-
mefantrine over 3 days. If this malaria treatment occurred at a
scheduled clinic visit, the patient was not given the trial medi-
cations for that visit.
Ethics Approvals
Ethical approval for the study was obtained from the ethics com-
mittee of the University of Ilorin Teaching Hospital and the Lon-
don School of Hygiene and Tropical Medicine. An independent
data safety monitoring board provided oversight for the trial.
RESULTS
Characteristics of the Study Participants at Enrollment
Patients were recruited from 26 September 2011 to 12 April
2012, and follow-up for the last patients ended in April 2013.
A total of 318 patients were screened; 270 who met inclusion
criteria were randomly assigned in a 1:1:1 ratio to receive
MQAS once every 2 months, SPAQ once every 2 months, or
daily proguanil. Baseline characteristics were similar in the 3
groups (Table 1 and Supplementary Table 1). Twenty-three of
270 samples (9%) were positive for P. falciparum by PCR at
baseline, of which 9 (39%) carried the mdr1 mutation N86Y,
Table 1. Baseline Characteristics of Study Participants, by
Prophylaxis Group
Variable
MQAS
Group
(n = 90)
SPAQ Group
(n = 90)
Proguanil
Group
(n = 90)
Female sex 45 41 43
Age, y
<5 30 29 24
5–9 28 28 31
10–14 18 21 21
15–25 14 12 14
Hb genotype
SC 1 (1.1) 5 (5.6) 6 (6.7)
SS 89 (99) 85 (94) 84 (93)
Hb concentration,
g/dL, mean (SD)
7.4 (1.3) 7.5 (1.6) 7.5 (1.7)
PCV, %, mean (SD) 24.6 (3.7) 25.1 (3.9) 24.6 (4.2)
Weight, kg,
median (SD)
22.9 (12.1) 21.9 (10.6) 22.9 (11.5)
Weight for age z
score ≤2
35 (39) 34 (38) 29 (32)
Slept under treated
net previous night
49 (54) 45 (50) 51 (57)
Prevalent
parasitemia
By microscopya 0 (0) 0 (0) 1 (1.4)
By PCR 11 (12.2) 6 (6.7) 6 (6.7)
Data are no. or no. (%) of patients, unless otherwise indicated.
Abbreviations: Hb, hemoglobin;MQAS,mefloquine-artesunate; PCR, polymerase
chain reaction; PCV, packed cell volume; SD, standard deviation; SPAQ,
sulfadoxine-pyrimethamine plus amodiaquine.
a Data are for 74 subjects in the MQAS group, 77 in the SPAQ group, and 73 in
the proguanil group.
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20 (87%) carried the dhfr triple mutations S108N, N51I, and
C59R, and 18 (78%) carried the dhps double mutations
A437G and K540E. The ﬂow of participants through the
study is shown in Figure 1.
Adherence
Doses of study drugs administered are shown in Supplementary
Table 2. Adherence to visits once every 2 months was good, with
most patients returning promptly at approximately 8-week in-
tervals (Supplementary Table 3). Pill counts at the clinic sug-
gested that all patients took both home doses of MQAS or
SPAQ, although this could not be veriﬁed. Adherence to daily
proguanil doses, also based on tablet counts at the clinic, was
poor, with 57% of patients using <75% of daily doses. Adher-
ence was better in children aged <10 years than in older children
(Supplementary Table 4).
Adverse Events
Severe illnesses requiring hospital admission were common in
all treatment groups (0.6 episodes/person during the study pe-
riod; Table 2). The most common causes for admission were
vasoocclusive crisis and septicemia (Supplementary Table 6).
Admissions were more frequent among female participants
than male participants, in all 3 groups. Less severe illnesses
treated in outpatient settings were most frequent in the progua-
nil group, especially among females. The protective efﬁcacy
against episodes of outpatient illness (calculated as the percentage
reduction in the number of episodes), compared with the progua-
nil group, was 23% (95% conﬁdence interval [CI], 0%–43%) for
MQAS and 25% (95% CI, 0%–44%) for SPAQ (Table 2). The ex-
cess number of outpatient illness episodes in the proguanil group
was mainly among females (interaction between sex and treat-
ment group, P = .023; Table 3).
Figure 1. Trial proﬁle. Each visit represents a bimonthly visit to the sickle cell clinic. Abbreviations: MQAS, meﬂoquine-artesunate; SP, sulfadoxine-
pyrimethamine; SPAQ, sulfadoxine-pyrimethamine plus amodiaquine.
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When participants were asked about side effects on day 3
after each bimonthly visit, vomiting, body pain, and abdominal
pain were the most frequently reported symptoms (Table 4) and
were reported more commonly by patients who received MQAS
and SPAQ than by those who received proguanil. Adverse
events were mostly mild in intensity (Supplementary Table 7).
An adverse event during the 3 days following treatment was re-
ported by 24% (95% CI, 19%–21%) of patients who received
MQAS, 14% (95% CI, 9.6%–18%) who received SPAQ, and
5.4% (95% CI, 3.4%–17%) who received proguanil (risk ratios,
4.5 [95% CI, 3.0–6.8] for the MQAS group vs the proguanil
group and 2.6 [95% CI, 1.6–4.1] for the SPAQ group vs the pro-
guanil group). A similar proportion of male and female partic-
ipants reported side effects on day 3. Among participants who
received MQAS, the risk of vomiting was substantially higher
for those who received MQ doses in excess of 35 mg/kg
(Supplementary Figure 1).
When participants were asked about side effects and illness
symptoms recorded in their diary in the 2 months prior to a
routine clinic visit, 18% in the proguanil group reported an ad-
verse event, compared with 13% in each of the other groups
(Table 4). Females who received proguanil were more likely
than males to report side effects (23% vs 14%; adverse event
risk ratio, 1.6 [95% CI, 1.1–2.3]), with body pain and abdominal
pain being the symptoms more commonly reported.
Seven participants died during the study (mortality rate, 25
deaths/1000 person-years). Four of these had received MQAS
(a girl aged 13 years admitted with vasoocclusive crisis precipitat-
ed by sepsis who had a blood culture positive for methicillin-
susceptible Staphylococcus aureus, a girl aged 6 years who died
at home with a suspected cerebrovascular accident, a boy aged
10 years admitted with severe anemia and sepsis, and a boy
aged 1 year with a febrile illness who died at home). Three deaths
were in the proguanil group (a girl aged 16 years with upper gas-
trointestinal tract bleeding associated with disseminated intravas-
cular coagulation, a girl aged 9 years with acute chest syndrome
with sepsis, and a girl aged 12 years who died at home from an
unknown cause). There were no deaths in the SPAQ group.
Table 2. Rates of Hospital Admissions and Outpatient Clinic Attendance for Illness
Variable
Hospital Admissiona Outpatient Clinic Attendance
Events, No. Annual Rate Adjusted RR (95% CI)b Events, No. Annual Rate Adjusted RR (95% CI)b
Prophylaxis group
Proguanil 59 0.61 1 140 1.4 1
MQAS 60 0.66 1.1 (.73–1.7) 107 1.2 0.77 (.57–1.0)
SPAQ 56 0.59 1.0 (.62–1.7) 104 1.1 0.75 (.56–1,0)
Age, y
<5 62 0.70 1 135 1.5 1
5–9 61 0.67 0.96 (.62–1.5) 113 1.2 0.77 (.59–1.0)
10–14 38 0.61 0.92 (.52–1.6) 58 0.92 0.59 (.41–.84)
≥15 14 0.34 0.51 (.26–1.0) 45 1.1 0.65 (.40–1.1)
Sex
Male 75 0.51 1 148 1 1
Female 100 0.73 1.5 (1.0–2.2) 203 1.5 1.5 (1.2–1.9)
Abbreviations: MQAS, mefloquine-artesunate; SPAQ, sulfadoxine-pyrimethamine plus amodiaquine.
a Data are for inpatients and patients who died.
b Rate ratios (RRs) and 95% confidence intervals (CIs) were estimated using Cox regression with a random effect to allow for repeat events in the same patient.
Analyses were adjusted for treatment group, age, and sex.
Table 3. Outpatient Attendance for Illness Among Male and Female Patients, by Prophylaxis Group
Prophylaxis
Group
Males Females
Events,
No.
Person-Years
at Risk, No.
Events/
Person-Year,
No. RR (95% CI)
Events,
No.
Person-Years
at Risk, No.
Events/
Person-Year,
No. RR (95% CI)
Proguanil 47 51.29 0.9 1 93 45.35 2.1 1
SPAQ 54 51.47 1.0 1.1 (.73–1.8) 50 43.63 1.1 0.56 (.37–.85)
MQAS 47 43.59 1.1 1.2 (.74–1.9) 60 47.51 1.3 0.62 (.42–.92)
Abbreviations: CI, confidence interval; MQAS, mefloquine-artesunate; RR, rate ratio; SPAQ, sulfadoxine-pyrimethamine plus amodiaquine.
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Efﬁcacy Against Malaria
Thirty-eight episodes of clinical malaria were recorded (15 in-
patients and 23 outpatients). Incidence was lower in the MQAS
group, with a relative protective efﬁcacy of 61% (95% CI, 3%–
84%), compared with the proguanil group. The relative efﬁcacy
of SPAQ versus that of proguanil was 36% (95% CI, −40% to
70%; Table 5). The prevalence of P. falciparum infection in sam-
ples taken from all participants at each scheduled clinic visit was
also lower in the MQAS group than the proguanil group (odds
ratio, 0.48; 95% CI, .22–1.0; Table 6. Mean hemoglobin concen-
tration 12 months after enrollment in the trial was similar in all
groups (Supplementary Table 8).
DISCUSSION
IPT with MQAS administered when patients with SCD came
for routine clinic visits was well-tolerated, mild adverse events,
the most common of which were vomiting and abdominal pain,
did not deter patients from returning for their clinic visits.
MQAS given once every 2 months was more effective in pre-
venting malaria than daily prophylaxis with proguanil. MQAS
reduced the prevalence of parasitemia at routine clinic as-
sessments and reduced all-cause illness episodes treated as out-
patients but did not reduce the burden of severe disease
requiring hospital admission. Adherence to daily proguanil
Table 4. Overall and 8 Most Common Incident Adverse Events Reported, by Time of Occurrence and Prophylaxis Group
Variable MQAS Group SPAQ Group Proguanil Group
On day 3 after each visit n = 583 n = 608 n = 595
Symptom, patients, %
Vomiting 8.9 2.0 0.0
Body pain 2.7 2.3 2.4
Abdominal pain 5.8 1.0 0.3
Weakness 2.1 4.4 0.5
Nausea 4.3 1.3 0.3
Headache 2.7 2.1 0.3
Fever 3.1 0.7 1.2
Dizziness 2.1 2.0 0.0
Any 24.0 13.8 5.4
RR (95% CI) 4.5 (3.0–6.8) 2.6 (1.6–4.1) 1
During interval between visits n = 554 n = 591 n = 579
Symptom, patients, %
Body pain 3.2 4.0 7.6
Fever 3.6 3.6 4.7
Cough 1.9 2.9 1.8
Abdominal pain 2.2 1.6 2.6
Headache 0.9 2.4 1.3
Other symptoms 0.8 1.3 2.5
Vomiting 1.1 0.5 0.9
Jaundice 0.5 0.2 1.0
Any 12.5 13.4 18.1
RR (95% CI) 0.68 (.51–.91) 0.74 (.55–.98) 1
Abbreviations: CI, confidence interval; MQAS, mefloquine-artesunate; RR, rate ratio; SPAQ, sulfadoxine-pyrimethamine plus amodiaquine.
Table 5. Incidence of Malaria Episodes, by Prophylaxis Group
Prophylaxis Group Participants, No.
Events,
No.
Person-Years
at Risk, No.
Events/Person-
Year, No.
Efficacy, %
(95% CI)
Proguanil 90 19 96.64 0.20 . . .
SPAQ 90 12 95.10 0.13 36 (−39 to 70)
MQAS 90 7 91.10 0.08 61 (2–84)
Abbreviations: CI, confidence interval; MQAS, mefloquine-artesunate; SPAQ, sulfadoxine-pyrimethamine plus amodiaquine.
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prophylaxis was suboptimal, and P. falciparum mutations asso-
ciated with antifolate resistance were common. Therefore, it is
likely that proguanil prophylaxis was ineffective, although the
study could not include a placebo group that would have al-
lowed this to be assessed. We did not ﬁnd that treatment with
SPAQ once every 2 months was more effective than proguanil
in preventing malaria episodes or reducing prevalence at rou-
tine visits, although there was a reduction in episodes of outpa-
tient illness among patients who received SPAQ. It is likely that
the gap between treatments was too long (2 months) for this
regimen to give a high degree of protection.
MQ can cause neurological and psychiatric side effects and
should not be used in patients with psychiatric illness or epilep-
sy [21]. However, these side effects have not been common
when MQ has been used for treatment in Asia, Latin America,
and Africa [22, 23]. Vomiting is a common MQ side effect and
is dose related, and its incidence was reduced by using a split
dose over 3 days. Tolerability of MQ treatment and prophylaxis
has been reviewed in children by Schlagenhauf et al [24] and in
pregnant women by Gonsalez et al [25]. In a study of MQAS for
the treatment of uncomplicated P. falciparum malaria under-
taken in Nigeria, Agomo et al [26] reported vomiting, dizziness,
headache, abdominal discomfort, weakness, and visceral pain as
common adverse events, consistent with the ﬁndings of our
study. Despite the occurrence of minor side effects, the majority
of the patients in the MQ arm, when asked, said they would pre-
fer to continue with the bimonthly MQAS after the end of the
study, rather than revert to daily administration of proguanil.
Illnesses treated in outpatient settings and reports of illness
symptoms recorded in patient diaries were more common
among female participants than among male participants who
took daily proguanil. Some other studies have reported that girls
with SCD can have more-frequent pain episodes than boys [27].
Sex-speciﬁc differences in adverse events have also been report-
ed for antimalarials used for prophylaxis [28]. The excess illness
in the proguanil group may reﬂect adverse reactions to progua-
nil or a sex-speciﬁc increase in illness episodes associated with
failure of prophylaxis.
The lack of an effect against hospital admissions in the
MQAS group, despite a high efﬁcacy against malaria, is consis-
tent with the low prevalence of malaria in the study population.
There was limited scope to demonstrate an impact on all-cause
admissions, but it is possible a greater beneﬁt would be seen in
areas with more intense malaria transmission. In the 2010 ma-
laria indicator survey in Nigeria, the national prevalence of
malaria in children aged <5 years in urban areas was 23%, com-
pared with 48% in rural areas [29].
Malaria prevention in patients with SCD using IPT with
long-acting antimalarials has a number of advantages. It is rec-
ommended that stable patients should attend a clinic every 2
months, and the IPT strategy can take advantage of these rou-
tine visits. The ﬁrst dose of the 3-day regimen can be adminis-
tered by clinic staff or directly observed, and adherence in
taking the further 2 doses is likely to be higher than that of a
regimen that requires daily treatment. The cost of the MQAS
regimen compares favorably with that of the proguanil regimen
(Supplementary Materials). Our trial was done in an area with
year-round transmission. In areas of highly seasonal transmis-
sion, chemoprevention could be limited to the transmission pe-
riod, as is now recommended for children aged <5 years in the
Sahel subregion [16]. In areas where seasonal malaria chemo-
prevention is provided, children <5 years old with SCD could
receive seasonal malaria chemoprevention as an alternative to
chemoprevention at SCD clinics.
Our study is larger than previous trials of malaria prophylaxis
in patients with SCD, with follow-up over a longer period, but it
had a number of weaknesses. We could not monitor adherence
directly, our estimates of the number of daily doses used were
based on pill counts at the clinic and probably overestimate ac-
tual adherence, and adherence to daily doses and return rates to
clinic may be poorer outside the context of the trial. It was not
feasible to blind our study, owing to difference in the number of
tablets to be taken and difﬁculty in adequate taste masking, and
this could have biased our assessment of adverse events. Report-
ed vomiting can include spitting out a tablet or a gag reﬂex on
administration, so data on the incidence of vomiting may over-
estimate the true incidence. The number of malaria events was
low (the study was powered primarily to assess tolerability), and
the estimates of efﬁcacy were correspondingly imprecise. We
did not investigate the pharmacokinetics of MQ used for bi-
monthly prophylaxis, and the incidence of malaria was too
low to be able to estimate duration of protection directly, but
such studies would be useful.
A high burden of severe disease was observed, with a rate of
0.6 episodes requiring admission per person per year and a
mortality rate of 25 episodes per 1000 persons per year. Addi-
tional strategies are needed to reduce the burden of severe dis-
ease in patients with SCD in Africa. In the United States, an
improvement in survival among patients with SCD has been at-
tributed to introduction of pneumococcal and Haemophilus
Table 6. Prevalence of Plasmodium falciparum Infections, by
Prophylaxis Group
Prophylaxis
Group
Overall
Visits, No.
Visits With
P. falciparum Detected
OR (95% CI)No.
Percentage
(95% CI)
Proguanil 353 21 5.9 (3.3–8.6) 1
SPAQ 365 24 6.6 (4.3–8.9) 1.1 (.61–2.0)
MQAS 340 10 2.9 (1.2–4.6) 0.48 (.22–1.0)
Abbreviations: CI, confidence interval; MQAS, mefloquine-artesunate; OR,
odds ratio; SPAQ, sulfadoxine-pyrimethamine plus amodiaquine.
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inﬂuenzae type b vaccination. Nigeria introduced pentavalent vac-
cine, which included H. inﬂuenzae type b vaccine, in 2012 and
plans to introduce pneumococcal vaccine, and the impact of
these vaccines on survival among patients with SCD needs to be
evaluated. A recent survey of SCD management practices in Nige-
ria [30] found that few provided penicillin prophylaxis or pneumo-
coccal vaccination for patients with SCD. All 18 clinics surveyed
provided malaria prophylaxis, but our study indicates that regi-
mens that are more effective than daily proguanil need to be used.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org). Supplementary materials consist of
data provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages regard-
ing errors should be addressed to the author.
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